
Kamal A Saeed
Examiner (ID: 17845, Phone: (571)272-0705 , Office: P/1626 )
| Most Active Art Unit | 1626 |
| Art Unit(s) | 1626 |
| Total Applications | 3118 |
| Issued Applications | 2322 |
| Pending Applications | 321 |
| Abandoned Applications | 524 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19826259
[patent_doc_number] => 12247024
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-11
[patent_title] => Process for preparing aficamten
[patent_app_type] => utility
[patent_app_number] => 18/468636
[patent_app_country] => US
[patent_app_date] => 2023-09-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15809
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18468636
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/468636 | Process for preparing aficamten | Sep 14, 2023 | Issued |
Array
(
[id] => 19536693
[patent_doc_number] => 12129234
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-10-29
[patent_title] => Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
[patent_app_type] => utility
[patent_app_number] => 18/368143
[patent_app_country] => US
[patent_app_date] => 2023-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 14268
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18368143
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/368143 | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine | Sep 13, 2023 | Issued |
Array
(
[id] => 18878991
[patent_doc_number] => 20240002360
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 18/459944
[patent_app_country] => US
[patent_app_date] => 2023-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31004
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459944
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/459944 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | Aug 31, 2023 | Abandoned |
Array
(
[id] => 18932231
[patent_doc_number] => 11884637
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-01-30
[patent_title] => 3-(4-chlorophenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl}-1,2,4-oxadiazole as an antitumor and antimicrobial compound
[patent_app_type] => utility
[patent_app_number] => 18/238713
[patent_app_country] => US
[patent_app_date] => 2023-08-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 3827
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18238713
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/238713 | 3-(4-chlorophenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl}-1,2,4-oxadiazole as an antitumor and antimicrobial compound | Aug 27, 2023 | Issued |
Array
(
[id] => 18815903
[patent_doc_number] => 20230390242
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => PYRROLE COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/453887
[patent_app_country] => US
[patent_app_date] => 2023-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28491
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18453887
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/453887 | PYRROLE COMPOUNDS | Aug 21, 2023 | Pending |
Array
(
[id] => 18844400
[patent_doc_number] => 20230406804
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => PROTEIN KINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/451630
[patent_app_country] => US
[patent_app_date] => 2023-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9261
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 118
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18451630
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/451630 | PROTEIN KINASE INHIBITORS | Aug 16, 2023 | Pending |
Array
(
[id] => 19172398
[patent_doc_number] => 20240158372
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/451757
[patent_app_country] => US
[patent_app_date] => 2023-08-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52259
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18451757
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/451757 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | Aug 16, 2023 | Abandoned |
Array
(
[id] => 18953512
[patent_doc_number] => 20240041839
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => METHODS OF INHIBITING TUMOR METASTASIS
[patent_app_type] => utility
[patent_app_number] => 18/448495
[patent_app_country] => US
[patent_app_date] => 2023-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9962
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448495
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/448495 | METHODS OF INHIBITING TUMOR METASTASIS | Aug 10, 2023 | Abandoned |
Array
(
[id] => 19762131
[patent_doc_number] => 12220401
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-11
[patent_title] => Compounds useful as kinase inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/362249
[patent_app_country] => US
[patent_app_date] => 2023-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71272
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18362249
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/362249 | Compounds useful as kinase inhibitors | Jul 30, 2023 | Issued |
Array
(
[id] => 19675828
[patent_doc_number] => 12187678
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-07
[patent_title] => Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators
[patent_app_type] => utility
[patent_app_number] => 18/360976
[patent_app_country] => US
[patent_app_date] => 2023-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 83693
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 270
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18360976
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/360976 | Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators | Jul 27, 2023 | Issued |
Array
(
[id] => 18971830
[patent_doc_number] => 20240051922
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => XANTHOHUMOL DERIVATIVES AND METHODS FOR MAKING AND USING
[patent_app_type] => utility
[patent_app_number] => 18/354848
[patent_app_country] => US
[patent_app_date] => 2023-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16716
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18354848
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/354848 | XANTHOHUMOL DERIVATIVES AND METHODS FOR MAKING AND USING | Jul 18, 2023 | Pending |
Array
(
[id] => 19003558
[patent_doc_number] => 20240067629
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-29
[patent_title] => THERAPEUTIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/223169
[patent_app_country] => US
[patent_app_date] => 2023-07-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26605
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18223169
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/223169 | THERAPEUTIC COMPOUNDS | Jul 17, 2023 | Abandoned |
Array
(
[id] => 18753845
[patent_doc_number] => 20230357147
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-09
[patent_title] => DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/353492
[patent_app_country] => US
[patent_app_date] => 2023-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34822
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18353492
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/353492 | Deuterated tryptamine derivatives and methods of use | Jul 16, 2023 | Issued |
Array
(
[id] => 19792128
[patent_doc_number] => 12233051
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-25
[patent_title] => Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase
[patent_app_type] => utility
[patent_app_number] => 18/352721
[patent_app_country] => US
[patent_app_date] => 2023-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 3
[patent_no_of_words] => 22242
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 445
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18352721
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/352721 | Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase | Jul 13, 2023 | Issued |
Array
(
[id] => 19202747
[patent_doc_number] => 20240174646
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/343415
[patent_app_country] => US
[patent_app_date] => 2023-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14386
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18343415
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/343415 | METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOF | Jun 27, 2023 | Abandoned |
Array
(
[id] => 19067092
[patent_doc_number] => 20240101518
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => MCT4 INHIBITORS FOR TREATING DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/337313
[patent_app_country] => US
[patent_app_date] => 2023-06-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23268
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18337313
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/337313 | MCT4 inhibitors for treating disease | Jun 18, 2023 | Issued |
Array
(
[id] => 18690879
[patent_doc_number] => 20230321041
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => BLEND CONTAINING CARBAMATE COMPOUND FOR PREVENTION, MITIGATION, OR TREATMENT OF SCHIZOPHRENIA
[patent_app_type] => utility
[patent_app_number] => 18/210215
[patent_app_country] => US
[patent_app_date] => 2023-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5354
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18210215
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/210215 | BLEND CONTAINING CARBAMATE COMPOUND FOR PREVENTION, MITIGATION, OR TREATMENT OF SCHIZOPHRENIA | Jun 14, 2023 | Pending |
Array
(
[id] => 19187719
[patent_doc_number] => 20240166632
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/331779
[patent_app_country] => US
[patent_app_date] => 2023-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20561
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18331779
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/331779 | PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF | Jun 7, 2023 | Pending |
Array
(
[id] => 18672953
[patent_doc_number] => 20230310407
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-05
[patent_title] => RADIATION MITIGATOR AND METHOD OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/207447
[patent_app_country] => US
[patent_app_date] => 2023-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12094
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18207447
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/207447 | Radiation mitigator and method of use thereof | Jun 7, 2023 | Issued |
Array
(
[id] => 18649346
[patent_doc_number] => 20230295140
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => INHIBITORS OF VAP-1
[patent_app_type] => utility
[patent_app_number] => 18/201715
[patent_app_country] => US
[patent_app_date] => 2023-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63922
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18201715
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/201715 | Inhibitors of VAP-1 | May 23, 2023 | Issued |